

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: BOREA ET AL.                      Group Art Unit: 1614  
Serial No.: 10/603,406                                      Examiner: Gembeh, Shirley V.  
Filed: June 24, 2003                                      Attorney Docket No.: PAT-0040-US-NP2  
For:        ENHANCING TREATMENT OF MDR CANCER WITH ADENOSINE A<sub>3</sub>  
              ANTAGONISTS

**Mail Stop: Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**Conf. No.: 4184**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In connection with the above identified Application No. 10/603,406, filed June 24, 2003, Applicants wish to call the Examiner's attention to U.S. Patent No. 6,921,825 to Baraldi et al, and the enclosed journal articles by Baraldi et al. entitled "Pyrozolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A<sub>3</sub> Adenosine Receptor Antagonists: Influence of the Chain at the N<sup>8</sup> Pyrazole Nitrogen" (*Journal of Medicinal Chemistry* 2000, 43, 4768-4780); and "Synthesis, Biological Activity, and Molecular Modeling Investigation of New Pyrozolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Human A<sub>3</sub> Adenosine Receptor Antagonists" (*Journal of Medicinal Chemistry* 2002, 45, 770-780).

It is estimated that no fees are required for filing this Paper. Notwithstanding, should the Commissioner determine otherwise, please charge any necessary fees to Deposit Account No. 50-3706 in the name of King Pharmaceuticals, Inc.

Respectfully submitted,



Paivi Kukkola  
(Reg. No. 50,499)

King Pharmaceuticals, Inc.  
400 Crossing Boulevard  
Bridgewater, NJ 08807  
Tel: (908) 429-6000 ext 58964  
Encl.: Form 1449/PTO

Date: November 15, 2007